Acrux Limited (ARUXF) Discusses Female Testosterone Therapy and Progress Toward Market for HSDD Transcript

Unknown Executive

Good morning, everyone, and welcome to this investor webinar for Acrux Limited. My name is [ Gaby Holles ]. I assist Acrux with Investor Relations. And joining me this morning is Acrux CEO, John Warmbrunn. Welcome, John.

John Warmbrunn
MD, CEO & Director

Thank you. Lovely to be here.

Unknown Executive

Before I hand over to John for the formal presentation, just a reminder that this webinar is being recorded, and there will be the opportunity to ask John some questions at the end of the presentation. [Operator Instructions]

Okay. Over to you, John.

John Warmbrunn
MD, CEO & Director

Okay. Thank you, and welcome, everybody. It’s a real pleasure to be here talking today. And the main topic I’m talking about is female testosterone and bring you up to speed with where we’re going and what’s happening. But — my slide isn’t clicking forward. gosh. My apologies. Why is my slide clicking forward.

Okay. Okay. Just a quick disclaimer as usual. But what I really want to talk about is female testosterone and where we’re at, and we’re in a great spot. We’ve got a Phase III assets. We’ve got a really big growth opportunity. We’re aiming to be first to market. We’ve got a unique product, and we’re also having success with our co-development pathway. So we’re in a great position to help millions of women with hypoactive sexual desire disorder.

So what is it? Some way to describe it is low Libido, but it’s not just low Libido. The impact of that flows through in a whole lot of different areas. And it’s very common. The classic numbers are